Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

Stephen Barat, Katyna Borroto-Esoda, Alan Ashbaugh, Melanie Cushion
ECCMID 2020
April 2020

CANDIMAD study: a prospective multi-centre laboratory based survey of antifungal resistance in Candida spp. causing invasive candidiasis in Madrid

Judith Diaz-Garcia, Aina Mesquida, María Ángeles Meléndez Carmona, Fernando González-Romo, Cuetara Maria Soledad, Nelly Daniela Zurita Cruz, Maria Muñoz Algarra, Maria Del Coral Garcia, Aída Sánchez, Inmaculada Quiles, Maria Teresa Duran-Valle, Carlos Sanchez-Carrillo, Patricia Muñoz, Pilar Escribano, Jesus Guinea Ortega
ECCMID 2020
April 2020

In Vitro Activity of Ibrexafungerp in pH 7.0 and pH 4.5 Testing Environments Against 187 Fluconazole-susceptible and -resistant Candida Species from Vulvovaginal Candidiasis Patients.

Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins

Clinical Experience of Oral Ibrexafungerp for Treatment of Four Patients with Invasive Candidiasis from the FURI Study

Juergen Prattes, Christoph Zurl, Robert Krause, Nkechi Azie, David Angulo
ECCMID 2020
April 2020

Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

BD Alexander, M Johnson, OA Cornely, PG Pappas, R Miller, J Vazquez,  L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli, TF Patterson, M Hoenigl, N. Azie, DA Angulo
ECCMID 2020
April 2020

In vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients

A Phase 2b, Dose Finding Study Evaluating Oral Ibrexafungerp in Moderate to Severe Acute Vulvovaginal Candidiasis (DOVE)

Aspergillus isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to Ibrexafungerp (SCY-078)

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study